# ARASAFE (NCT05676203)

> A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

No report yet. It can be ordered.

- Drugs tested: docetaxel
- Indication: metastatic hormone-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05676203
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Jena University Hospital
- Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Interventions: Standard ADT (androgen deprivation therapy); Standard Darolutamide; Docetaxel
- Enrollment: 250
- Primary outcome: Rate of grade 3-5 AEs

## Indexed commentary on ARASAFE so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=arasafe-nct05676203

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05676203", "email": "<work email>"}; the inbox owner confirms by the emailed link.